Business Wire

A More Efficient, Innovative and Greener 11.11 Runs Wholly on Alibaba Cloud

Share

Alibaba Cloud, the digital technology and intelligence backbone of Alibaba Group, has once again excelled in its mission of supporting the group’s 11.11 Global Shopping Festival, thanks to its high-performance computing and innovative technology. Drawing on self-developed infrastructure upgrades, the group saw an 8% year-on-year saving in computing cost per resource unit from April 1 to November 11.

“The breadth and depth of cloud technology deployment during this year’s 11.11 has once again showcased Alibaba’s best cloud and technology practice; be it through fundamental architecture like self-proprietary technology powering high-performance computing and database products, or consumer-facing XR (extended reality) and livestreaming technologies. We intend to continue applying these proven capabilities to even better serve our customers and help them to be more efficient, innovative and greener in their own digital transformation journeys,” said Li Cheng, Chief Technology Officer (CTO) of Alibaba Group.

Doing more with less through cloud-native and serverless innovations

This year’s 11.11 was powered by Alibaba Cloud’s dedicated processing unit for the Apsara Cloud operating system. The upgraded infrastructure system, significantly improved efficiency of computing, storage and network in data centers supporting the event, while also reducing network latency. For example, with this new upgrade supported by cloud-native technology, ordering, pre-sale balance payment and refunding could be launched simultaneously with an enhanced scalability and lower latency.

During this year’s 11.11, the front page of Taobao, one of Alibaba’s e-commerce platforms, was upgraded by the latest serverless technology, allowing for automatic scaling with extreme elasticity based on actual workloads.

Alibaba Cloud’s cloud-native database products also significantly expanded the capacity of consumers’ shopping carts by more than a double, from 120 items to 300. The ApsaraDB for Redis Enhanced Edition (Tair), a cloud-based in-memory database service for enterprises, supports new functions such as product grouping and sorting, enabling consumers to organize their shopping cart according to their own preferences. They could also make use of the ‘select’ function to enjoy cross-merchant discounts, to pre-order goods and use vouchers for a more rewarding shopping experience.

Innovative technology delivers more immersive consumer experience

A more immersive shopping experience was created this year thanks to Alibaba’s proprietary technology in supporting extended reality. Alibaba’s technology in 3D modeling leverages a neural radiance field (NeRF), a neural network technology for generating novel views of complex 3D scenes. During this year’s 11.11, it assisted luxurious retail and furniture brands, like Burberry, Estee Lauder and SK-II, to build virtual stores on the e-commerce platform Tmall.

Through self-developed 3D renderings that realistically represent natural light, flames and natural flowing water, an outdoor nature scene was built for sportswear brands including Descente (Japan), to showcase its latest products in a vibrant and invigorating environment. Consumers can also view the products in three dimensions, enabling them to inspect details up close, or try on their chosen watches and accessories virtually thanks to AR technologies. Consumers are also free to arrange different items of furniture indoors, or tents for outdoor camping.

Another new expressive interaction came from an XR-powered marketplace on Tmall and Taobao. Using the automatic 3D space creation technology from Alibaba’s research institute DAMO Academy, a virtual shopping street was built, featuring over 700 products from 70 brands including 30 internationally-recognized franchises, such as Sanrio’s iconic Hello Kitty, and Hollywood’s franchise Minions. Shoppers can choose their own avatars, check out the products and place them in their virtual shopping carts.

During this year’s 12-day festival from October 31 to November 11, nearly 2 million packages were delivered by Xiaomanlv vehicles, Alibaba’s last-mile logistics vehicle. This is double the package delivery volume from the same period last year. The logistics robot was deployed in over 400 campuses across China, which has greatly reduced the time of queuing for package deliveries during peak hours.

A greener 11.11 powered by clean energy

In addition to its cloud computing solutions helping to reduce energy consumption, Alibaba Cloud’s five hyper-scale data centers across China also doubled the amount of clean energy used to support this year’s 11.11 compared to last year. More than 32 million kilowatt-hours of electricity used by Alibaba Cloud to support 11.11 this year came from renewable energy, up by 30% on a daily basis average compared to last year. Additionally, Alibaba Cloud's Heyuan data center, the cloud company’s largest hyper-scale data center in South China, now runs entirely on clean energy. Alibaba Cloud’s self-developed immersion cooling technology has reduced the energy consumption of the data centers, with power usage effectiveness (PUE) reaching as low as 1.09 - a world-leading level.

Alibaba Cloud has also worked with Tmall to leverage the carbon management platform, Energy Expert. It provided online carbon footprint modeling, calculations and certifications for more than 40 brands in various sectors, including paper & pulp, food and personal care, to help them categorize low-carbon products, identify carbon emission resources and conduct informed sustainability practices to reduce carbon emissions.

About Alibaba Cloud

Established in 2009, Alibaba Cloud (www.alibabacloud.com) is the digital technology and intelligence backbone of Alibaba Group. It offers a complete suite of cloud services to customers worldwide, including elastic computing, database, storage, network virtualization services, large-scale computing, security, management and application services, big data analytics, a machine learning platform and IoT services. Alibaba maintained its position as the third leading public cloud IaaS service provider globally since 2018, according to IDC. Alibaba is the world’s third leading and Asia Pacific’s leading IaaS provider by revenue in U.S. dollars since 2018, according to Gartner.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Xiaoyi Shao
Alibaba Group
+86 18658170996
shaoxiaoyi.sxy@alibaba-inc.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye